What should be the primary target of "treat to target" in psoriatic arthritis?

What should be the primary target of "treat to target" in psoriatic arthritis?

<h4>Background</h4> <p>Treat to Target in psoriatic arthritis (PsA) recommendations have stated that the target should be remission or inactive disease. Potential definitions include Very Low Disease Activity (VLDA), PsA Disease Activity Score (PASDAS) near remission, Disease Act...

Bibliográfalaš dieđut
Váldodahkkit:	Coates, LC, Lubrano, E, Perrotta, FM, Emery, P, Conaghan, PG, Helliwell, PS
Materiálatiipa:	Journal article
Giella:	English
Almmustuhtton:	Journal of Rheumatology 2018

Geahča maid

What should be the primary target of ‘treat to target’ in PsA?
Dahkki: Coates, L, et al.
Almmustuhtton: (2018)

Treat-to-target in psoriatic arthritis—cost-effective in the biosimilar era
Dahkki: Coates, L, et al.
Almmustuhtton: (2022)

Long-term follow-up of patients in the TIght COntrol of inflammation in early Psoriatic Arthritis (TICOPA) trial
Dahkki: Coates, L, et al.
Almmustuhtton: (2019)

Sustained very low disease activity and remission in psoriatic arthritis patients
Dahkki: Lubrano, E, et al.
Almmustuhtton: (2019)

Secukinumab for ankylosing spondylitis and psoriatic arthritis
Dahkki: Lubrano E, et al.
Almmustuhtton: (2016-10-01)

New approved drugs for psoriatic arthritis
Dahkki: F.M. Perrotta, et al.
Almmustuhtton: (2016-09-01)

Precision medicine in psoriatic arthritis: how should we select targeted therapies?
Dahkki: Al-Mossawi, H, et al.
Almmustuhtton: (2019)

Sustained Very Low Disease Activity and Remission in Psoriatic Arthritis Patients
Dahkki: Ennio Lubrano, et al.
Almmustuhtton: (2019-08-01)

How should we define disease and outcomes in axial psoriatic arthritis?
Dahkki: Coates, LC
Almmustuhtton: (2021)

Difficult to Treat and Refractory to Treatment in Psoriatic Arthritis
Dahkki: Ennio Lubrano, et al.
Almmustuhtton: (2023-07-01)

THE DIAGNOSIS OF PSORIATIC ARTHRITIS
Dahkki: P.S. Helliwell
Almmustuhtton: (2011-09-01)

The dynamics of response as measured by multiple composite outcome tools in the TIght COntrol of inflammation in early Psoriatic Arthritis (TICOPA) trial.
Dahkki: Coates, L, et al.
Almmustuhtton: (2017)

Does treat to target or achieving remission improve radiographic outcome in psa?
Dahkki: Coates, L, et al.
Almmustuhtton: (2016)

Simulation-based design of pragmatic trials in psoriatic arthritis using propensity scores
Dahkki: Weinstein, SM, et al.
Almmustuhtton: (2021)

Novel concepts in psoriatic arthritis management: Can we treat to target?
Dahkki: Tucker, L, et al.
Almmustuhtton: (2018)

Mixed methods study of clinicians’ perspectives on barriers to implementation of treat to target in psoriatic arthritis
Dahkki: Dures, E, et al.
Almmustuhtton: (2020)

Comparing the visual analogue scale and the numerical rating scale in patient-reported outcomes in psoriatic arthritis
Dahkki: Ye, W, et al.
Almmustuhtton: (2021)

Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo
Dahkki: Gladman, DD, et al.
Almmustuhtton: (2022)

The comparative performance of three screening questionnaires for psoriatic arthritis in a primary care surveillance study
Dahkki: Helliwell, PS, et al.
Almmustuhtton: (2023)

Assessment of patient-physician interactions in psoriatic arthritis: national results of the ASSIST Study
Dahkki: Perrotta, FM, et al.
Almmustuhtton: (2024)

Measuring physical function in psoriatic arthritis: comparing the Multi-Dimensional Health Assessment Questionnaire to the Health Assessment Questionnaire Disability Index
Dahkki: Ye, W, et al.
Almmustuhtton: (2021)

Occult axial involvement in patients with psoriatic arthritis mutilans: a case report
Dahkki: F.M. Perrotta, et al.
Almmustuhtton: (2019-07-01)

Current concepts and unmet needs in psoriatic arthritis
Dahkki: Mahmood, F, et al.
Almmustuhtton: (2017)

Psoriatic arthritis: prospects for the future
Dahkki: Hackett, S, et al.
Almmustuhtton: (2022)

Should methotrexate have any place in the treatment of psoriatic arthritis?
Dahkki: Ye, W, et al.
Almmustuhtton: (2019)

Evaluation and validation of a patient completed psoriatic arthritis flare questionnaire
Dahkki: Helliwell, PS, et al.
Almmustuhtton: (2021)

Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same?
Dahkki: Coates, L, et al.
Almmustuhtton: (2016)

Measuring outcomes in psoriatic arthritis
Dahkki: Ogdie, A, et al.
Almmustuhtton: (2020)

Outcome measures in psoriatic arthritis: where next?
Dahkki: Hackett, S, et al.
Almmustuhtton: (2022)

Sequencing of Biologic and Target Synthetic Disease-Modifying Anti-Rheumatic Drugs in Psoriatic Arthritis: Are we Ready to Redefine the Treatment Strategy? A Perspective
Dahkki: Ennio Lubrano, et al.
Almmustuhtton: (2022-12-01)

Psoriatic arthritis: lessons from imaging studies and implications for therapy
Dahkki: Mathew, A, et al.
Almmustuhtton: (2016)

Assessing disease activity in psoriatic arthritis: a literature review
Dahkki: Tucker, L, et al.
Almmustuhtton: (2018)

Treatment to target in psoriatic arthritis with apremilast: probability of achieving targets and comprehensive control of disease manifestations
Dahkki: Mease, PJ, et al.
Almmustuhtton: (2020)

Comparing psoriatic arthritis low-field magnetic resonance imaging, ultrasound and clinical outcomes: data from the TICOPA trial
Dahkki: Helliwell, P, et al.
Almmustuhtton: (2019)

Cost-effectiveness of tight control of inflammation in early psoriatic arthritis: economic analysis of a multicenter randomized controlled trial
Dahkki: O'Dwyer, J, et al.
Almmustuhtton: (2018)

Remission in psoriatic arthritis—where are we now?
Dahkki: Coates, L, et al.
Almmustuhtton: (2017)

Identification of psoriatic arthritis in patients with psoriasis
Dahkki: Coates, LC, et al.
Almmustuhtton: (2023)

GRAPPA 2021 treatment recommendations for psoriatic arthritis
Dahkki: Soriano, ER, et al.
Almmustuhtton: (2023)

Psoriatic arthritis: imaging techniques
Dahkki: E. Lubrano, et al.
Almmustuhtton: (2012-06-01)

Validation of new potential targets for remission and low disease activity in psoriatic arthritis in patients treated with golimumab
Dahkki: Coates, L, et al.
Almmustuhtton: (2018)